# A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

> **NCT06602219** · PHASE2 · COMPLETED · sponsor: **DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 222 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** LY4100511
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06602219
- **Lead sponsor:** DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-25
- **Primary completion:** 2025-07-24
- **Final completion:** 2025-09-04
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602219, "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06602219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*